GENERIC BOOM FORECAST FOR 2011-2012
JUNE 01, 2007
Brand name prescription drugs with annual sales of >$140 billion are in line to lose patent protection between now and 2016, according to a new analysis that bodes well for the generic pharmaceutical industry?s prospects during the coming decade. The analysis by researchers at Data-monitor predicts that the peak of the patent expirations will occur during 2011 and 2012, when heavily prescribed branded products such as clopi-dogrel bisulfate (Plavix), atorvas-tatin calcium (Lipitor), fluticasone propionate and salmeterol inhalation powder (Advair), and queti-apine fumarate (Seroquel) will face generic competition for the first time.
Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo.